Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Athersys Inc (NQ: ATHX )

1.940 USD +0.110 (+6.01%)
Official Closing Price Updated: 7:53 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Athersys Inc

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma
UTHealth and Athersys announce patient enrollment in an innovative clinical study of MultiStem® cell therapy for the treatment of traumatic injuries 
From Business Wire News Releases
Athersys Announces Three Appointments to Board of Directors
Athersys announces three appointments to its board of directors, deepening board expertise to prepare for future growth and commercialization. 
From Business Wire News Releases
Athersys Reports Third Quarter 2020 Results and Provides Corporate Update
Athersys announces Q3 earnings and initiation of MultiStem® Phase 2 clinical trial in patients with trauma related inflammation and complications 
From Business Wire News Releases
Athersys to Host Third Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2020 financial results on Monday, November 9, 2020. 
From Business Wire News Releases
Thinking about buying stock in Athersys, Party City, AcelRx Pharmaceuticals, Southwest Airlines, or Carnival Corp?
InvestorsObserver issues critical PriceWatch Alerts for ATHX, PRTY, ACRX, LUV, and CCL. 
From PR Newswire
FDA Grants RMAT Designation to MultiStem Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome
MultiStem is the only cell therapy program for acute respiratory distress syndrome (ARDS) that has both Fast Track and RMAT designation from the FDA. 
From Business Wire News Releases
Athersys Reports Second Quarter 2020 Results
Athersys has made progress during Q2 in key clinical programs and infrastructure to support its planned transition to becoming a commercial company. 
From Business Wire News Releases
Athersys to Host Second Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2020 financial results on Monday, August 10, 2020. 
From Business Wire News Releases
Thinking about buying stock in SINTX Technologies, China Automotive Systems, Athersys Inc, Theratechnologies, or Biocept Inc?
InvestorsObserver issues critical PriceWatch Alerts for SINT, CAAS, ATHX, THTX, and BIOC. 
From PR Newswire
Athersys Announces Upcoming Presentations at the International Society of Cell and Gene Therapy Virtual Conference
Athersys taking a leading role at the International Society of Cell ad Gene Therapy Conference and will discuss MultiStem and the ARDS clinical trial. 
From Business Wire News Releases
Athersys Reports First Quarter 2020 Results
Athersys Q1 Earnings reflects multiple achievements for the Company, including obtaining FDA authorization to initiate two additional clinical trials. 
From Business Wire News Releases
Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS
The first patients have been enrolled in the Athersys COVID-19 induced ARDS clinical program using MultiStem cell therapy. 
From Business Wire News Releases
Athersys and University Hospitals Cleveland Medical Center Announce Activation of the First Clinical Site for the MACOVIA Study, a Pivotal Phase 2/3 Study Evaluating MultiStem® Cell Therapy for COVID-
The first clinical site is now open for the MACOVIA study, a pivotal Phase 2/3 study evaluating MultiStem® cell therapy for COVID-19 induced ARDS 
From Business Wire News Releases
Athersys to Present at the Bank of America Merrill Lynch Virtual Healthcare Conference on May 14
Athersys presentation scheduled for May 14, 2020 at 8:20 AM EDT. A live webcast will be available at https://tinyurl.com/y73g9zud 
From Business Wire News Releases
Athersys to Host First Quarter Financial Results Call
Athersys will release its first quarter 2020 financial results at approximately 4:00 PM Eastern Time on Thursday, May 7, 2020. 
From Business Wire News Releases
Athersys Announces Closing of Public Offering of Common Stock
Athersys, Inc. (NASDAQ: ATHX) (Athersys) today announced the closing of its previously announced underwritten public offering of 25,587,500 shares of its common stock, par value $0.001 per share... 
From Business Wire News Releases
Athersys Announces Pricing of Public Offering of Common Stock
Athersys, Inc. (NASDAQ: ATHX) (Athersys) today announced the pricing of its previously announced underwritten public offering of its common stock, par value $0.001 per share (Common Stock), at a price... 
From Business Wire News Releases
Athersys Announces Proposed Public Offering of Common Stock
Athersys, Inc. (NASDAQ: ATHX) (Athersys) announced today that it intends to offer for sale $50 million of shares of its common stock, par value $0.001 per share (Common Stock), in an underwritten... 
From Business Wire News Releases
FDA Authorizes Initiation of a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma Patients
Phase 2 study of cell therapy in trauma expands Company’s clinical programs focused on critical care 
From Business Wire News Releases
FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome
Company plans to initiate a Phase 2/3 pivotal study in patients with COVID-19 induced ARDS this quarter 
From Business Wire News Releases
Vaccine For COVID-19 Health Crises “Possible” By Summer After FDA Fast-Tracks Clinical Trials
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Vaccine for COVID-19 Health Crises "Possible" by Summer After FDA Fast-Tracks Clinical Trials
Financialnewsmedia.com News Commentary 
From PR Newswire
HEALIOS K.K. Increases Investment in Athersys by Fully Exercising Warrant to Acquire Additional Shares
Healios purchased 4,000,000 shares representing an additional investment of $7,040,000 in Athersys. 
From Business Wire News Releases
Athersys Names Maia Hansen Senior Vice President, Operations and Supply Chain
Maia Hansen appointed to help Athersys to establish and manage a sustainable supply chain to support commercial success. 
From Business Wire News Releases
Athersys Announces Financial Results for Fourth Quarter and Full Year 2019
Clinical trial results in ARDS supported designation by BARDA as a "Highly Relevant" program for COVID-19 and other pathogens. 
From Business Wire News Releases
NetworkNewsBreaks – Athersys Inc. (NASDAQ: ATHX) Featured in Dawson James Research Report
From InvestorBrandNetwork
Athersys to Host Year-End 2019 Financial Results Call
Athersys will host year-end 2019 financial results call on March 16, 2020. 
From Business Wire News Releases
Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Athersys, Inc. (“Athersys” or the “Company”) (NASDAQ: ATHX) announced today that, as previously disclosed in its Form 8-K filed with the Securities and Exchange Commission on January 16, 2020, the... 
From Business Wire News Releases
Athersys Names Ivor Macleod Chief Financial Officer
Highly experienced pharmaceutical industry executive joins leadership team as Company begins planning for potential approval and commercialization of MultiStem® 
From GlobeNewswire News Releases
Athersys Provides Update on One-Year ARDS Study Data
One-year results support positive 28-day findings and suggest further benefits for ARDS patients 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.